Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  AbbVie    ABBV

ABBVIE (ABBV)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

AbbVie : Leukaemia patients to get access to AbbVies Venclyxto via Cancer Drugs Fund

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/06/2017 | 12:11pm CET

The new treatment Venclyxto (venetoclax) is to be available to NHS patients in England with chronic lymphocytic leukaemia (CLL), the common form of adult leukaemia via the CDF while it accrues more cost-effectiveness data.

Venclyxto will be available to adults with difficult-to-treat types of chronic lymphocytic leukaemia those patients without 17p deletion or TP53 mutation who have failed both chemo-immunotherapy and a B-cell receptor (BCR) inhibitor.

Venclyxto has also been recommended for the treatment of adult CLL patients in the presence of 17p deletion or TP53 mutation who are either unsuitable for or have failed a BCR inhibitor.

The decision represents a U-turn from NICE, which had rejected Venclyxto in first draft guidance published in February.

But since then AbbVie has been in talks with NICE and in final guidance, the cost-effectiveness watchdog granted interim funding from the CDF.

This will allow NICE to gather further evidence to address uncertainties in the dossier of trial evidence submitted by AbbVie, while giving CLL patients a further treatment option when other drugs have failed.

One concern cited by NICE was how generalisable the results of trials were to clinical practice in England, as neither the M12-175 nor M14-032 trials included any UK centres.

NICE also questioned evidence showing that despite having several therapies, CLL appeared not to have a detrimental effect on health-related quality of life of patients in the Venclyxto trials.

The committee concluded that patients in the trials were not as sick as those for whom the drug would be an option in England, meaning the treatment benefits in the population were uncertain.

Although data showed overall survival was much higher with Venclyxto, NICEs independent appraisal committee said the relative survival benefit compared with best supportive care was likely to be biased in favour of Venclexto.

Venclexto is likely to cost between 50,000-60,000 per Quality Adjusted Life Year gained, above the 30,000 threshold usually used by NICE but it has extra leeway as end of life criteria apply.

Dr Peter Hillmen, professor of Experimental Haematology and honorary consultant haematologist at Leeds Teaching Hospitals NHS Trust, said: Todays recommendation is great news for patients with CLL who have failed existing treatments, and provides clinicians with an important new treatment option.

The studies that NICE has assessed to reach this positive decision represent a milestone in the management of relapsed/refractory CLL.

The early clinical data is compelling, showing survival benefits for this challenging group of patients, including some who achieved complete remission. I would anticipate that collection of further data through the CDF will confirm these extremely promising early findings.

Alice Butler, medical director at AbbVie, said: Working together with the NHS to collect more long-term data provides an important opportunity to understand the impact of venetoclax on the survival of patients with this difficult-to-treat type of CLL.

Patients in Wales are likely to get access to drug in the coming months following NICEs ruling, while the Scottish Medicines Consortium already recommended funding in August in a separate decision.

(c) Copyright: Arab News 2017 All rights reserved. Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ABBVIE
06:06a ABBVIE : 36 Saudis graduate from AbbVie’s pharma training program
12/11 ABBVIE : IMBRUVICA® (ibrutinib) Data Provide Insights Into Its Potential Treatme..
12/09 ABBVIE : IMBRUVICA® (ibrutinib) Pooled Analysis Suggests Benefit in Progression-..
12/09 ABBVIE : IMBRUVICA® (ibrutinib) Patient-Reported Outcomes Data Detail Long-Term ..
12/07 ABBVIE : IMBRUVICA plus Rituximab Phase 3 iNNOVATE Trial in Rare Waldenstrom's M..
12/06 ABBVIE : AbbVies IL-23 blocker shows efficacy in psoriasis trial
12/05 MARKETS RIGHT NOW : US stocks open mostly higher
12/05 ABBVIE : Risankizumab Meets All Primary Endpoints Reporting Positive Results in ..
12/05 ABBVIE : IMBRUVICA® (ibrutinib) Plus Rituximab Phase 3 iNNOVATE Trial in Rare Wa..
12/04 ABBVIE : Risankizumab Meets All Primary Endpoints Reporting Positive Results in ..
More news
News from SeekingAlpha
12/11 Buy Celgene And Regeneron On The Dips As Insiders Are Buying
12/10 Dividend Income Update November 2017
12/06 BIOTECH ANALYSIS CENTRAL PHARMA NEWS : Madrigal's NASH Success, AbbVie's Phase 3..
12/06 Buy Biotech ETF IBB And Trim Semiconductor Stocks
12/06 3 THINGS IN BIOTECH YOU SHOULD LEARN : December 6, 2017
Financials ($)
Sales 2017 27 998 M
EBIT 2017 11 955 M
Net income 2017 7 316 M
Debt 2017 26 790 M
Yield 2017 2,70%
P/E ratio 2017 20,80
P/E ratio 2018 16,40
EV / Sales 2017 6,45x
EV / Sales 2018 5,71x
Capitalization 154 B
Chart ABBVIE
Duration : Period :
AbbVie Technical Analysis Chart | ABBV | US00287Y1091 | 4-Traders
Technical analysis trends ABBVIE
Short TermMid-TermLong Term
TrendsBullishBullishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 99,9 $
Spread / Average Target 3,5%
EPS Revisions
Managers
NameTitle
Richard A. Gonzalez Chairman & Chief Executive Officer
Azita Saleki-Gerhardt Senior Vice President-Operations
William J. Chase Chief Financial Officer & Executive Vice President
Michael E. Severino Chief Scientific Officer & Executive VP
Robert J. Alpern Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ABBVIE50.50%153 782
MERCK KGAA-10.38%13 516
KYOWA HAKKO KIRIN CO LTD31.58%10 547
JAZZ PHARMACEUTICALS PLC23.66%8 331
ZHANGZHOU PIENTZEHUANG PHARMACEUTICL LTD37.43%5 735
CONVATEC GROUP-10.13%5 528